Skip to content

Search

Showing results for "lung disease preterm"

OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule

Combination vaccines containing whole-cell pertussis antigens were phased out from the Australian national immunisation programme between 1997 and 1999 and replaced by the less reactogenic acellular pertussis (aP) antigens. In a large case-control study of Australian children born during the transition period, those with allergist diagnosed IgE-mediated food allergy were less likely to have received whole-cell vaccine in early infancy than matched population controls (OR: 0.77 (95% CI, 0.62 to 0.95)). We hypothesise that a single dose of whole-cell vaccine in early infancy is protective against IgE-mediated food allergy.

2016 Round 1 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the 4 successful applications for the 2016 Round 1 Wesfarmers Centre Seed Funding.

Multiple Breath Washout Outcomes Are Sensitive to Inflammation and Infection in Children with Cystic Fibrosis

Multiple Breath Washout Outcomes Are Sensitive to Inflammation and Infection in Children with Cystic Fibrosis The multiple breath washout technique

Are you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis media

Are you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis media

Safety, tolerability, and effect of a single aural dose of Dornase alfa at the time of ventilation tube surgery for otitis media: A Phase 1b double randomized control trial

One third of children require repeat ventilation tube insertion (VTI) for otitis media. Disease recurrence is associated with persistent middle ear bacterial biofilms. With demonstration that Dornase alfa (a DNase) disrupts middle ear effusion biofilms ex vivo, we identified potential for this as an anti-biofilm therapy to prevent repeat VTI. First, safety and tolerability needed to be measured.

The COSI-2 Trial

Tobias Jenny Strunk Mountain MD, PhD, FRACP MBA MClinEpi Head, Neonatal Health Program Manager, Neonatal Health / Protect Trial tobias.strunk@

Editorial: Immunity in Compromised Newborns

Tobias Strunk MD, PhD, FRACP Head, Neonatal Health tobias.strunk@thekids.org.au Head, Neonatal Health Clinical Professor Tobias Strunk is a

Cerebral Palsy

A non-progressive motor disability due to damage of the developing brain, this is the most common physical disability in childhood. Affecting about one in 500 babies, it is frequently accompanied by other neurological impairments, such as intellectual or sensory.

Cerebral Palsy Respiratory Health

We know from research that the risk of death from respiratory disease is 14 times higher for adults with cerebral palsy than for other adults. Respiratory disease is the most common cause of premature death in children and young people with cerebral palsy and one of the main causes of hospitalisation.

Pcv7-and pcv10-vaccinated otitis-prone children in new zealand have similar pneumococcal and haemophilus influenzae densities in their nasopharynx and middle ear

PCV10 did not reduce NTHi density in the nasopharynx or middle ear, and was associated with increased pneumococcal nasopharyngeal density